

UKPIN Steering Group			
Name	Personal Interests	Honoraria	Connections
Claire Bethune	none	Travel and registration at ESID 2014 – sponsored by Grifols	Company sponsored trials, Aware – Novartis, IOS –Shire, GammaTrack - Octapharma
Matthew Buckland	none	DMC Chair for Octapharma, No other honoraria/company fees	Biocryst – commercial study, Grifols and Octapharma – Commercial studies, Shire – Commercial studies
Emily Carne	Nil	Ad board attendance BPL, Baxter, CSL, Shire ESID attendance 2014 CSL Behring registration, accommodation and travel	Studies run by Novartis, Biocryst, BPL, Baxter, GSK
David Edgar	Shareholder, Time for Medicine Limited.	EAACI June 2014: Shire sponsored travel/accommodation and registration, IAAI June 2014: Meeting sponsored by multiple companies to include delegate accommodation (1 night) Lecture fees X1 from ALK-Abello	None
Suzanne Elcombe	No declaration received	No declaration received	No declaration received
Tomaz Garcez	Nothing to declare	Nothing to declare for period April 2014 to current	My department contributes to the Icatibant Outcome Study and hosts the research nurses for the UK-PIN registry
Richard Herriot	Shareholder, Time for Medicine Limited.	None.	2014 travel grants to departmental nursing staff from Grifols UK Ltd and Shire Pharmaceuticals Ltd.
Rashmi Jain	none	Sponsorship to go for educational meetings (ESID, BSACI, Global HAE forum 2014)	Cost of illness study conducted by ViroPharma
Stephen Jolles	Time for Medicine Ltd - shareholder	No declaration received	Conference, Advisory Board, Clinical Trials and Projects with CSL Behring, Baxter/Baxalta, Biotest, Grifols, Binding Site, BPL, UCB Pharma, Octapharma, Biocryst, Novartis, Shire, Thermofisher and SOBI.
Dinakantha Kumararatne	I have None	Grant to Attend AAAAI Congress Feb2014 (Registration, Travel, Hotel) : CSLBehring. Grant to attend EAACI June 2014 (Registration, Travel, Hotel): Shire Honorarium for lecture on SCIG therapy : Baxter Dec 2014	None
Sara Marshall	No conflicting personal interests identified	Acted as expert witness for one medicolegal case in 2014-2015, No honoraria or travel awards accepted.	No conflicting departmental interests identified
Ravishankar Sargur	none	Support for attending ESID 2014 – Shire Pharmaceuticals.	Novartis – PI for Glacial and AWARE studies. MEDA pharmaceuticals – PI for DYMISTA study
Gavin Spickett	none	Previously received travel grants from Allergy Therapeutics, Baxter. Received lecture fees from ALK	None currently
Kimberly Gilmour	None	Octapharma to speak and attend the JMF European meeting 7/8 May 2015 (travel, accommodation and donation to GOSH charity). Centre for Chronic Immunodeficiencies (Freiberg)to teach at the CID summer school (June 2015)- travel and accommodation. ESID to speak at ESID (OCT 2014), travel, accommodation and registration	None (note laboratory department is separate from clinical department)
Peter Arkwright	NONE	NONE	NONE
Christine Symons	No known personal interest: stocks and shares ISA may include pharmaceutical companies.	Over the years I have received educational grants to attend national and international meetings. I received a grant towards the cost of an MSc. Module. I have received honoraria for advisory groups. Companies for all of the above include: ALK Abello, Grifols, Shire/Viropharma, CSL Behring, Octapharma. I also sit on the Advisory Panels of HAEUK and UKPIPS.	The Department is currently involved in commercial trials with Shire and Novartis. We have concluded one with Octapharma. We have previously worked with CSL Behring and Shire. We are working towards a trial with Grifols. We are part of STILPAD (Investgator led) and our in-house Dig trial. We recruit for the ESID/UKPIN Databa

Bill Egner	No shares held directly in any company related to PID	No honoraria or consultation fees. Cannot recall any honoraria or travel grants/subsidy for PID related activities in past 5 years	Research studies only: I am an investigator not PI. IGBOT QoL study. Laboratory may have contracts with companies involved in diagnostics and pharmaceuticals e.g Grifols but I am not closely involved in any contract award processes. UK NEQAS may interfere with similar companies but is strictly independent and I follow their COI policy. In past, have done IVIG studies but none for >5 years
------------	---	--	---